Molecular Partners
From Wikipedia, the free encyclopedia
 | |
| Company type | Public |
|---|---|
| SIX: MOLN Nasdaq: MOLN | |
| Industry | Biotechnology |
| Founded | 2004 |
| Headquarters | Schlieren, canton of Zürich, Switzerland |
Key people |
|
| Total assets | CHF 145.6 million (Mar. 31, 2021)[1] |
Number of employees | 152 FTE (Mar. 31, 2021) [1] |
| Website | molecularpartners |
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland.[2] The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins,[3] with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.[1]
Researchers at the University of Zürich, Switzerland formed Molecular Partners AG in 2004 while studying monoclonal antibodies. These scientists discovered and developed the DARPin technology and launched the company using this platform.[3]
Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange (ticker MOLN).[4][5]
Since July 2021, the company is also listed on the Nasdaq in the US under the ticker symbol MOLN.[6]
